A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Jae-Cheol JoYoung-Woo JeonDa Jung KimDeok-Hwan YangWon Sik LeeYoon Seok ChoiJun Ho YiDok Hyun YoonJee Hyun KongJung-Yoon ChoeSungHyun KimKeumYoung AhnTaeHong ParkHana JuSoonbum KwonSeok-Goo ChoPublished in: Expert opinion on biological therapy (2023)
Findings were consistent with the known CT-P10/reference rituximab safety profile, with high effectiveness observed in NHL/CLL and RA.
Keyphrases
- clinical practice
- chronic lymphocytic leukemia
- randomized controlled trial
- image quality
- diffuse large b cell lymphoma
- dual energy
- computed tomography
- systematic review
- contrast enhanced
- public health
- rheumatoid arthritis
- hodgkin lymphoma
- positron emission tomography
- magnetic resonance imaging
- magnetic resonance
- disease activity
- ankylosing spondylitis
- systemic sclerosis
- interstitial lung disease
- idiopathic pulmonary fibrosis